New Pharma will crowd out Big Pharma
The author is a Reuters Breakingviews columnist. The opinions expressed are her own.
By Aimee Donnellan
LONDON, June 11 (Reuters Breakingviews) -Big Pharma is under threat from tech-driven upstart rivals. The values of large, established players like $159 billion Pfizer PFE.N, $230 billion Novartis NOVN.S and $216 billion Roche ROG.S are converging with newer players like $121 billion Vertex Pharmaceuticals VRTX.O. As drugmakers wrestle with the need to constantly replenish their stocks of remedies via deals, big names may struggle to remain relevant.
Big Pharma companies have taken over a century to become market leaders. Swiss giant Roche was founded in 1896, while U.S. drugmaker Pfizer has been around since 1849, when typhoid and scarlet fever were among the biggest killers. Both giants came to dominate the industry by making savvy calls on common diseases, like cancer and infectious ailments. M&A is also a critical part of their growth story – witness Roche’s $47 billion takeover of Genentech in 2009, and Pfizer’s $43 billion purchase of cancer specialist Seagen in 2023.
But now a new breed of tech-savvy drugmakers, once the obvious prey of their established rivals, are threatening their dominance. Over the past five years, Amgen AMGN.O, Regeneron REGN.O, Genmab GMAB.CO and Vertex have added $270 billion to their combined market values. That compares to Big Pharma firms like Pfizer, Novartis, GSK GSK.L, Sanofi SASY.PA and Roche, whose aggregate market value has declined by nearly $80 billion in the same period.
The growth of the once bite-sized drugmakers is already creating a hotter climate for takeovers. Last year, the value of biopharma M&A increased by 79% to $152 billion. In 2022, $164 billion Amgen, which is now roughly the same size as Pfizer after increasing fivefold since 2010, splurged $28 billion on Horizon Therapeutics. Analysts reckon Horizon had been on a list of deal targets for more established players for some time.
This increased competition comes at a particularly inopportune moment for executives from traditional drugmakers like Pfizer, Merck MRK.N and GSK, all of which will gradually lose patent exclusivity on some of their top-selling drugs. Merck’s patent on its cancer drug Keytruda, which delivered over $25 billion in sales in 2023, expires in four years. The United States’ Inflation Reduction Act also gives biologic drugs, which are created by using living cells and were historically made by smaller technology-driven drugmakers, longer patents than more established drugs like insulin and antihistamines. That puts an even greater value on the companies that make those newer products.
Deals are often the quickest way of replenishing a drug cupboard. But if there is increased competition, the price of smaller drugmakers will spike. AbbVie’s ABBV.N $10 billion purchase of ImmunoGen earlier this year included an eye-watering 95% premium, suggesting the trend is already in full swing. There are also fewer obvious targets to choose from. In 2022 new drug approvals in the U.S. were down by a quarter, to the lowest level since 2016. Eventually, today’s Big Pharma and their biotech challengers may swap places.
Follow @aimeedonnellan on X
Graphic: Tech-driven drugmakers’ market values are closing in on Big Pharma https://reut.rs/3x2Hy3x
Editing by George Hay and Oliver Taslic
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
